We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





New Line of Immunoassay Stabilizers Launched at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
Image: Immunoassay stabilizers give assay developers the best possible tool to lower non-specific binding and maximize the signal-to-noise ratios of immunoassays (Photo courtesy of Surmodics).
The launch and immediate availability of a new line of advanced immunoassay stabilizers were announced prior to the commencement of the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Surmodics (Eden Prairie, MN, USA) StabilBlock Immunoassay Stabilizer, which will be on display in Booth 4047 of the expo, is advertised as the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.

Surmodics offers a family of immunoassay stabilizers, which preserve the conformation and activity of dried proteins on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity. With StabilCoat, StabilGuard, and the new StabilBlock immunoassay stabilizers, the company now offers three options to assay developers with a combination of blocking efficacy and long-term dried stability that is unmatched in the industry.

“As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers,” said Joe Stich, vice- president and general manager of Surmodics IVD. “We recognize that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilizers will enable assay developers to achieve the best results for each application.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Surmodics



Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Automatic Photometer
JOLLY 103
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus
New
Molecular Diagnostic System
FlashDetect Flash48

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.